A significant difference was observed between the two different TP53 signature groups with respect to ER, PR, HER2, tumor grade, histological type, need for postoperative adjuvant chemotherapy and need for postoperative adjuvant endocrine therapy. The gene discussed is ERBB2; the disease is neoplasm.